Predictors of corticosteroid‐dependent and corticosteroid‐refractory inflammatory bowel disease: analysis of a Chinese cohort study
暂无分享,去创建一个
V. Wong | F. Chan | J. Sung | K. Tsoi | F. Chan | J. Sung | R. Leong | D. K. Chow | J. Wu | V. W. Wong | D. K. Chow | K. Tsoi | Rupert Leong
[1] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[2] T. Piche. Impact de la chirurgie gynécologique sur le développement du syndrome de l’intestin irritable et des douleurs abdominales , 2008 .
[3] F. Chan,et al. Changes in Crohn's disease phenotype over time in the Chinese population: Validation of the Montreal classification system , 2008, Inflammatory bowel diseases.
[4] A. Zinsmeister,et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.
[5] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[6] S. Hutfless,et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. , 2007, Gastroenterology.
[7] Gerald Gartlehner,et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[9] G. Leandro,et al. Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission , 2007, The American Journal of Gastroenterology.
[10] A. Zinsmeister,et al. A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis , 2006, Inflammatory bowel diseases.
[11] H. Drummond,et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohort , 2006, Alimentary pharmacology & therapeutics.
[12] S. Dorn. Predictors of Crohn's disease. , 2006, Gastroenterology.
[13] J. Mary,et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.
[14] W. Tremaine,et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.
[15] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[16] P. Rutgeerts,et al. Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy , 2005 .
[17] J. Sung,et al. The Epidemiology and Phenotype of Crohn’s Disease in the Chinese Population , 2004, Inflammatory bowel diseases.
[18] S. Travis,et al. Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.
[19] P. Hellström,et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County , 2004, Gut.
[20] A. Zinsmeister,et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.
[21] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee , 2004, American Journal of Gastroenterology.
[22] G. Rogler,et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease , 2002, American Journal of Gastroenterology.
[23] A. Zinsmeister,et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.
[24] P. Keeling,et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. , 2000, Gastroenterology.
[25] J. Belaiche,et al. Clinical pattern of corticosteroid dependent Crohn's disease , 1998, European journal of gastroenterology & hepatology.
[26] J. Berlin,et al. Risk factors for early postoperative recurrence of Crohn's disease. , 1998, Gastroenterology.
[27] P. Munkholm,et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.
[28] P. Munkholm,et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.
[29] J. Lennard-jones,et al. Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.
[30] G. Hellers,et al. Prognosis and mortality of ulcerative colitis in Stockholm County, 1955-1979. , 1987, Scandinavian journal of gastroenterology.
[31] K. Ewe,et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.
[32] R. Fraser,et al. CAPTOPRIL, ANGIOTENSIN II, AND SODIUM IN BLOOD-PRESSURE REGULATION , 1979, The Lancet.
[33] R. Summers,et al. National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.
[34] J. Lennard-jones,et al. CLINICAL OUTCOME OF THE FIRST TEN YEARS OF ULCERATIVE COLITIS AND PROCTITIS , 1978, The Lancet.
[35] S. Truelove,et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.
[36] S. Truelove,et al. Cortisone in Ulcerative Colitis , 1954 .